Zoetis Secures EUA for Simparica Trio to Combat New World Screwworm in Dogs — Zoetis Inc.

Event summary

Zoetis' Simparica Trio received Emergency Use Authorization from the FDA on August 13, 2026 for treating New World screwworm infestations in dogs and puppies.
The EUA comes as several U.S. states have issued orders requiring treatment of domestic animals due to the spreading threat of New World screwworm.
Simparica Trio is already FDA-approved for heartworm disease, ticks, fleas, roundworms, hookworms, and flea tapeworm infections in dogs.
Zoetis also offers Dectomax-CA1 Injectable for treating New World screwworm in cattle under a separate EUA.

The big picture

This EUA underscores the growing threat of New World screwworm in the U.S., positioning Zoetis as a key player in emergency animal health solutions. The authorization builds on Zoetis' existing portfolio, reinforcing its strategy of providing comprehensive parasite protection across multiple species. As regulatory frameworks adapt to emerging zoonotic threats, companies like Zoetis stand to benefit from their ability to rapidly develop and deploy targeted treatments.

What we're watching

Regulatory Dynamics: How the FDA's EUA framework will shape Zoetis' ability to respond to emerging animal health threats.
Market Expansion: Whether Zoetis can leverage this authorization to strengthen its position in both companion animal and livestock markets.
Execution Risk: The pace at which Zoetis can scale production and distribution of Simparica Trio to meet potential demand spikes.